Skip to main content
Site map
Print this page
Alert service
Downloads
Glossary
Home
About us
Products
Partnering
Investors
Media
Contact us
Press releases
Image gallery
Contacts
Print this page
Bookmark page
Email us
Home
/
Media
/
Press releases
/
Archive
Archive
Register for our Alert Service
if you would like to be alerted when a news release is added to the site.
2012
2011
2010
2009
2008
2007
Archive
2006
Date
Title
21 Dec 2006
Vectura announces US collaboration agreement for its combination asthma therapy - VR315
13 Dec 2006
Vectura EGM approves the recommended offer for Innovata plc
29 Nov 2006
Vectura Announces that QVA149 Clinical Development starts in 2007 and Updates the Status of NVA237
17 Nov 2006
Interim Results for six months ended 30 September 2006
17 Nov 2006
Planned acquisition of Innovata plc by Vectura
16 Nov 2006
Vectura spin-out PharmaKodex Ltd raises £7.1m
28 Sep 2006
Annual General Meeting
08 Aug 2006
Vectura announces successful outcome of phase II study on inhaled parkinson’s disease product – VR040
24 Jul 2006
Vectura EGM approves £45 million new share Placing
28 Jun 2006
Vectura and Sosei announce successful outcome of Phase IIb study for NVA237
28 Jun 2006
Vectura announces successful outcome of Phase IIb study for VR004
28 Jun 2006
Vectura announces intention to complete £45m placing
25 May 2006
Preliminary Results for the Year Ended 31 March 2006
15 May 2006
Vectura and Unilever Ventures announce the spin out of Pharmakodex, a new speciality pharmaceutical company
19 Apr 2006
Vectura announces agreement with Boehringer Ingelheim on a new inhaler
04 Apr 2006
Vectura Announces First Product Deal in GyroHaler®
18 Jan 2006
Vectura Announces EMEA Orphan Drug Designation for its Inhaled Product for Parkinson’s Disease
2005
Date
Title
16 Nov 2005
Interim results for six months ended 30 September 2005
17 Oct 2005
Arakis and Vectura announce start of Phase IIb trial of NVA237 for COPD
17 Oct 2005
Notification of Interim Results
12 Sep 2005
Vectura Group plc announces change of Corporate Advisor
12 Sep 2005
Annual General Meeting Trading Update
22 Jun 2005
Preliminary results for the year ended 31 March 2005
13 Apr 2005
Arakis and Vectura announce agreement on new therapy for respiratory disease
2004
Date
Title
10 Nov 2004
Interim Results for six months ended 30th September 2004
25 Jun 2004
Vectura announces successful completion of IPO
02 Jun 2004
Vectura and SkyePharma form strategic alliance for pulmonary delivery technologies
26 May 2004
Vectura announces second successful clinical study on erectile dysfunction product
17 May 2004
Arakis and Vectura announce positive data from Phase IIa trial of COPD drug
2003
Date
Title
13 Oct 2003
Vectura CSO awarded West Technology Entrepreneur of the Year
18 Aug 2003
Arakis and Vectura announces Phase IIa trial for COPD drug
21 Jul 2003
Vectura announces positive data from clinical trial on its treatment for erectile dysfunction
25 Mar 2003
Vectura's novel erectile dysfunction treatment enters clinical trials in Europe
2002
Date
Title
04 Dec 2002
Vectura and GlaxoSmithKline sign dry powder drug formulation deal
06 Jun 2002
Vectura and Zambon complete licensing deal
11 Feb 2002
Vectura acquires rights to a novel Dry Powder Inhaler device
2001
Date
Title
12 Jul 2001
Chiesi and Vectura extend collaboration in pMDI field
05 Jun 2001
Vectura and Ranbaxy to collaborate on a novel oral controlled-released system
24 Apr 2001
Vectura completes £10.55 Million financing to advance drug delivery programmes
30 Mar 2001
Vectura announces appointment of Jack Cashman to the position of Non-Executive Chairman of its Board of Directors
2000
Date
Title
29 Nov 2000
Vectura and Arakis collaborate to develop a novel inhaled treatment for COPD
23 May 2000
Vectura and Chiesi to develop inhaled HFA systems for systemic drug delivery
1999
Date
Title
18 Aug 1999
Vectura acquires Co-ordinated Drug Development Ltd and assumes responsibility for the Centre for Drug Formulation Studies, to create 30-strong R&D team
24 Feb 1999
Vectura Ltd. receives £1.75 million from the Merlin Fund LP, the dedicated bioscience venture capital fund
Disclaimer
Privacy statement
Trademarks
Accessibility
Terms and Conditions